Taking a Closer Look at Recurrent/Metastatic SCCHN

Introduction

Current Treatment Guidelines for Recurrent/Metastatic SCCHN

EXTREME Study Design

Platinum-Based Chemotherapy Plus Cetuximab: EXTREME Trial

EXTREME Trial: Hazard Ratios for Death

EXTREME Trial: Hazard Ratios for Disease Progression

EXTREME Trial: Safety Profile

Limitations of the EXTREME Regimen

KEYNOTE-048 Study Design

OS: P vs E, in the CPS ≥ 1% and CPS ≥ 20% Populations

PFS: P vs E, in the CPS ≥ 1% and CPS ≥ 20% Populations

Response Summary: P vs E (Confirmed Responses)

KEYNOTE-048 Safety Results, P vs E, Total Population

OS and PFS: P + CT vs E, Total Population

Response Summary, P + CT vs E, Total Population (Confirmed Responses)

KEYNOTE-048 Safety Results, P + CT vs E, Total Population

How Might These Data Influence the Current Treatment Algorithm?

Limitations of KEYNOTE-048

PD-L1 Positivity of ICs and TCs Among Different Primary Tumor Site

How Might These Data Influence the Current Treatment Algorithm? (cont)

PD-L1 Data From the IMPASSION130 Study (TNBC)

Potential Implications of KEYNOTE-048 on Choice of Second-Line Therapy

Some Promising Immunotherapies Agents Under Development in SCCHN

SD-101 + Pembrolizumab in Anti-PD-1/PD-L1 Treatment-Naive R/M SCCHN (SYNERGY-001)

M7824 (MSB0011359C) in Advanced SCCHN: Results From a Phase 1 Cohort

Durvalumab + Danvatirsen or CX2i: Phase 1b/2 (SCORES)

Monalizumab + Cetuximab: Phase 2 Study

Conclusions

Abbreviations

Abbreviations (cont)